Merck
CN
  • The mito-DAMP cardiolipin blocks IL-10 production causing persistent inflammation during bacterial pneumonia.

The mito-DAMP cardiolipin blocks IL-10 production causing persistent inflammation during bacterial pneumonia.

Nature communications (2017-01-12)
Krishnendu Chakraborty, Mahesh Raundhal, Bill B Chen, Christina Morse, Yulia Y Tyurina, Anupriya Khare, Timothy B Oriss, Rachael Huff, Janet S Lee, Claudette M St Croix, Simon Watkins, Rama K Mallampalli, Valerian E Kagan, Anuradha Ray, Prabir Ray
ABSTRACT

Bacterial pneumonia is a significant healthcare burden worldwide. Failure to resolve inflammation after infection precipitates lung injury and an increase in morbidity and mortality. Gram-negative bacteria are common in pneumonia and increased levels of the mito-damage-associated molecular pattern (DAMP) cardiolipin can be detected in the lungs. Here we show that mice infected with Klebsiella pneumoniae develop lung injury with accumulation of cardiolipin. Cardiolipin inhibits resolution of inflammation by suppressing production of anti-inflammatory IL-10 by lung CD11b+Ly6GintLy6CloF4/80+ cells. Cardiolipin induces PPARγ SUMOylation, which causes recruitment of a repressive NCOR/HDAC3 complex to the IL-10 promoter, but not the TNF promoter, thereby tipping the balance towards inflammation rather than resolution. Inhibition of HDAC activity by sodium butyrate enhances recruitment of acetylated histone 3 to the IL-10 promoter and increases the concentration of IL-10 in the lungs. These findings identify a mechanism of persistent inflammation during pneumonia and indicate the potential of HDAC inhibition as a therapy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Rosiglitazone, ≥98% (HPLC)
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O26:B6, ≥10,000 EU/mg, purified by phenol extraction
Sigma-Aldrich
Sodium butyrate, ≥98.5% (GC)
Avanti
Heart CA, Avanti Polar Lipids
Avanti
Heart CA, Avanti Polar Lipids 840012P, powder